EOFlow Submits Application to the U.S. FDA for its Wearable Insulin Pump 'EOPatch'
* Plans to finalize its U.S. distribution strategy in 2023 * Aims to enter the U.S., the world's largest diabetes market, with its current disposable wearable insulin pump 'EOPatch' SAN JOSE, Calif. , Dec. 27, 2022 /PRNewswire/ -- EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a p...
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
* Establishment of Joint Venture Company named SanPlena in the US * Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. SirStephen Bloom , world-renowned researcher in the field of obesity and metabolism at Imp...